Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
The most recent EPS for Merck & Co Inc is $-1.28, not beating expectations of $-1.52.
How did Merck & Co Inc MRK's revenue perform in the last quarter?
Merck & Co Inc revenue for the last quarter is $-1.28
What is the revenue estimate for Merck & Co Inc?
According to 18 of Wall street analyst, the revenue estimate of Merck & Co Inc range from $18.11B to $15.53B
What's the earning quality score for Merck & Co Inc?
Merck & Co Inc has a earning quality score of A-/69.83095. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Merck & Co Inc report earnings?
Merck & Co Inc next earnings report is expected in 2026-07-29
What are Merck & Co Inc's expected earnings?
Merck & Co Inc expected earnings is $15.98B, according to wall-street analysts.
Did Merck & Co Inc beat earnings expectations?
Merck & Co Inc recent earnings of $16.28B beat expectations.